Navigation Links
New York Law Firm Files Lawsuit Against Manufacturer of Zicam Nasal Spray and Drugstore Chain That Sold Product
Date:7/8/2009

Leading personal injury law firm files complaint, alleging permanent damage to Long Island man's sense of smell and taste

Mineola, N.Y.(Lexis Nexis) July 8, 2009 -- Marc Grossman, senior partner of leading national personal injury law firm of Sanders Viener Grossman, LLP, in Mineola, N.Y., today announced that his firm has filed a civil lawsuit against the manufacturer of the popular Zicam nasal spray and the national drugstore chain that sold the product to a New York man who is alleging permanent injuries from his use of Zicam.

The lawsuit, Coleman et al v. Matrixx Intiatives, Inc. et al (Case Number 2:09-cv-2838), was filed last Thursday in the U.S. District Court, Eastern District of New York. The complaint alleges that Donald Coleman, a Bohemia, N.Y. resident, purchased a bottle of "Zicam Cold Remedy Nasal Spray" at a CVS Pharmacy store. After using the spray for about a week, and although the label stated it was "safe and effective" and a "patented homeopathic" remedy for cold symptoms, Mr. Coleman claims that he permanently lost his senses of smell and taste.

On June 16, 2009, the U.S. Food and Drug Administration (FDA) issued a public health advisory warning consumers to stop using and discard Zicam Cold Remedy Nasal Spray products, because the agency received greater than 130 reports of Anosmia, the medical term for a loss of smell and taste. As an over-the-counter product, neither the Zicam Cold Remedy Nasal Spray nor its labeling has ever been approved by the FDA.

"This is a clear example of an unregulated and unsafe product masquerading as a product that promotes good health" said Mr. Grossman, who is representing Mr. Coleman and numerous other individuals who used Zicam. "Rather than a minor cold, Mr. Coleman now has a permanent injury that deprives him of enjoying foods and aromas that he loved. The suspected culprit is zinc gluconate, listed as the active ingredient in Zicam products."

According to Mr. Grossman, zinc has long been purported as a cure for the common cold, but clinical studies dating back to 1937 have demonstrated that the application of substances containing zinc ions to the lining of the sinuses is toxic to cells that act as "smell receptors." As these cells die, so does not only one's sense of smell, but also taste.

Sanders Viener Grossman, LLP is one of the largest national law firms specializing in protecting the rights of innocent victims who have suffered personal injury as the result of the negligence of others. The firm is well-known for its successful litigation in a wide range of personal injury and products liability cases involving allegedly defective drugs, including headline-grabbing matters against Pfizer, Merck and other leading pharmaceutical companies.

For more information about Sanders Viener Grossman, LLP, please visit www.thesandersfirm.com or call 1.800.FAIRPLAY.

###

Read the full story at http://www.prweb.com/releases/2009/07/prweb2611684.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. CareFusion Files Amended Form 10 Registration Statement With SEC
2. Novo Nordisk Insulin Analogs Have Proven Safety Profiles
3. Discus Dental Files Suit to Protect BriteSmile(R) Trademark
4. WuXi PharmaTech Files 2008 Annual Report on Form 20-F
5. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
6. Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders
7. Watson Files FDA Application for Generic Mucinex(R) D
8. Profiles International Releases New Report on Top 5 Management Failures and Remedies for Success
9. Johnson & Johnson Files Arbitration Demand Against Schering-Plough to Resolve Dispute Over Agreements for REMICADE(R) and SIMPONI(TM)
10. CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS)
11. Mindray Files Annual Report on Form 20-F with U.S. Securities and Exchange Commission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
(Date:10/12/2017)... GRAND RAPIDS, Mich. (PRWEB) , ... October 12, ... ... OnSite Wellness, has been named one of Michigan’s 2017 Best and Brightest in ... Best and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: